

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Hansoh Pharmaceutical Group Company Limited**  
**翰森製藥集團有限公司**  
*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 3692)**

**VOLUNTARY ANNOUNCEMENT**

**DRUG REGISTRATION APPROVAL OF  
“EMPAGLIFLOZIN TABLETS”**

The board of directors (the “**Board**”) of Hansoh Pharmaceutical Group Company Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) is pleased to announce that “Empagliflozin Tablets” (the “**Product**”), developed by Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (江蘇豪森藥業集團有限公司), a subsidiary of the Company, has been granted drug registration approval by the National Medical Products Administration of the People’s Republic of China.

The Product is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The obtaining of drug registration approval of the Product will further enrich and improve the diabetes pipeline of the Group.

By Order of the Board  
**Hansoh Pharmaceutical Group Company Limited**  
**Zhong Huijuan**  
*Chairlady*

Hong Kong, July 31, 2020

*As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Miss Sun Yuan as executive directors, Ms. Ma Cuifang as non-executive director, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.*